Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 11, 2025

Background Using common clinical parameters, we aimed to noninvasively identify and predict metabolic dysfunction – associated steatohepatitis (MASH)/MASH with clinically significant fibrosis.

Language: Английский

---

Clinical Outcomes in Biopsy-Confirmed Steatotic Liver Disease: A Multicenter Prospective Cohort Study

Published: Jan. 1, 2025

Language: Английский

---

The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study

BMC Gastroenterology, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 17, 2025

Language: Английский

---

Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography

Clinical Ultrasound, Journal Year: 2024, Volume and Issue: 9(2), P. 70 - 84

Published: Nov. 30, 2024

Chronic liver diseases (CLD) are a major global health issue, with fibrosis progression and cirrhosis as critical determinants of prognosis treatment strategy. Historically, biopsy has been the gold standard for assessing fibrosis, but limitations such invasiveness, variability in results, cost have spurred development non-invasive tests. Elastography techniques measure stiffness, providing important insights into severity across various CLDs, including hepatitis B C metabolic dysfunction-associated steatotic disease (MASLD). Ultrasound-based elastography include vibration-controlled transient (VCTE), point shear wave elastography, 2D elastography. Most studies report high accuracy diagnosing significant cirrhosis. While VCTE is most widely used method, each technique strengths different patient populations, affected by factors like alanine aminotransaminase levels, obesity, presence hepatic inflammation. proves valuable informations decisions patients "gray zone" helps identify high-risk groups requiring post-hepatitis eradication surveillance. Recent emphasize potential elastography-based scores, FibroScan-AST AGILE improving diagnostic MASLD. However, performance may vary setting, validation primary care. Emerging precision medicine approaches, integrating genomics novel biomarkers, promise to further enhance risk stratification CLD management. Despite substantial advances, broader clinical application related biomarkers necessitates validation, particularly diverse care settings, ensure their optimal utility routine practice.

Language: Английский

---

Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease

Korean Journal of Medicine, Journal Year: 2024, Volume and Issue: 99(5), P. 232 - 239

Published: Oct. 1, 2024

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis patients with liver disease, making its accurate assessment essential for managing chronic disease. Traditionally, biopsy has been the standard method evaluating hepatic fibrosis. However, due to invasive nature limitation of sampling only small portion liver, it not suitable widespread use disease patients. Recently, there growing interest noninvasive tests assessing fibrosis, including imaging techniques serum biomarkers. These are being continuously developed increasingly utilized evaluate inform clinical practice. This paper reviews recent trends methods based on studies published date.

Language: Английский

---

Age serves as the silent architect of FIB-4's precision in unveiling advanced hepatic fibrosis in MASLD with T2DM

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Language: Английский

---